1470 PROSTATE RE-BIOPSY OUTCOMES AND CHANGE IN QOL STATUS AT 1-YEAR AFTER ACTIVE SURVEILLANCE IN JAPANESE PROSTATE CANCER PATIENTS-FROM A JAPANESE AS STUDY AND THE PRIAS-JAPAN-

Abstract

You have accessJournal of UrologyProstate Cancer: Localized VII1 Apr 20121470 PROSTATE RE-BIOPSY OUTCOMES AND CHANGE IN QOL STATUS AT 1-YEAR AFTER ACTIVE SURVEILLANCE IN JAPANESE PROSTATE CANCER PATIENTS-FROM A JAPANESE AS STUDY AND THE PRIAS-JAPAN- Mikio Sugimoto, Hiromi Hirama, and Yoshiyuki Kakehi Mikio SugimotoMikio Sugimoto Kagawa, Japan More articles by this author , Hiromi HiramaHiromi Hirama Kagawa, Japan More articles by this author , and Yoshiyuki KakehiYoshiyuki Kakehi Kagawa, Japan More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.02.1991AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES In Japan, two prospective multicentre active surveillance (AS) studies are under investigation. The 1st is a prospective Japanese multi-center AS study that has been carried out in favorable risk prostate cancer since 2002. The 2nd is the PRIAS-JAPAN; 30 institutions in Japan have been participating into the Prostate cancer Research International: Active Surveillance (PRIAS) study as the PRIAS-JAPAN since 2010. The objective of this study is to evaluate the outcomes of one-year after AS including prostate re-biopsy and the change in QOL status using the two Japanese prospective cohorts. METHODS 13 institutions participated in the Japanese multi-center AS study. 134 patients with biopsy proven prostate cancer that met the following criteria were enrolled into study between January 2002 and December 2003. The selection criteria included (1) stage T1cN0M0, (2) age 50-80, (3) serum prostate specific antigen (PSA) <20 ng/ml, (4) one or two positive cores per 6-12 systematic biopsy cores, (5) Gleason score <6, and (6) maximum cancer involvement in positive core <50%. Triggers to start curable treatment were PSADT of 2 years or shorter or pathological progression at 1-year re-biopsy.AS remaining rate in 33.2% (median observation period: 78 months). On the other hand, PRIAS-JAPAN study was started since January 2010. Until August 2011, 150 patients were enrolled. 1-year after re-biopsy was recommended to all participants and QOL was assessed at enrollment and at 1-year after AS in both studies with Japanese version SF-36 and SF-8 respectively. RESULTS In the Japanese multi-center AS study, although 99 patients were eligible for re-biopsy, only 66 out of 99 patients underwent. In 66 patients who underwent re-biopsy, 44 met the pathological selection criteria again, including 25 patients in whom biopsy turned negative. Reclassification rate was 33.3%. In PRIAS-JAPAN, reclassification rate was 20% (p=0.214). Almost all domains of QOL at enrollment revealed better QOL than that of general population with comparable ages. At 1-year after AS, there was no significant change and favorable QOL was maintained in both study. CONCLUSIONS Instead of the time difference between the 2 studies was approximately 10 years, reclassification rate for the current AS cohort (PRIAS-J) was comparable or even lower than the former cohort. Health-related QOL of the Japanese patients who opted AS as an initial treatment was favorable as compared to the age-matched Japanese population and it has been maintained 1-year after AS. © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 187Issue 4SApril 2012Page: e596 Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.MetricsAuthor Information Mikio Sugimoto Kagawa, Japan More articles by this author Hiromi Hirama Kagawa, Japan More articles by this author Yoshiyuki Kakehi Kagawa, Japan More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...